Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next
Sep 08
Have your own idea? Try our Stock Screener
Markets has moved to Discover
You can now access Markets by navigating to Discover and selecting Markets.
U.K. (FTSE) Biotech Industry Analysis
UpdatedSep 07, 2024
DataAggregated Company Financials
Companies23
- 7D-3.2%
- 3M-3.2%
- 1Y-21.7%
- YTD-19.6%
Over the last 7 days, the Biotech industry has dropped 3.2%, driven by Genus declining 4.1%. In contrast, Faron Pharmaceuticals Oy has gained 9.3%. Overall the industry is down 22% in 12 months. Looking forward, earnings are forecast to grow by 37% annually.
Industry Valuation and Performance
Has the U.K. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 08 Sep 2024 | UK£2.7b | UK£830.5m | -UK£314,446,085.32 | 82.9x | -8.7x | 3.3x |
| Tue, 06 Aug 2024 | UK£2.6b | UK£838.2m | -UK£257,829,540.40 | 30.2x | -9.9x | 3x |
| Thu, 04 Jul 2024 | UK£2.5b | UK£835.6m | -UK£260,780,212.79 | 30.1x | -9.8x | 3.1x |
| Sat, 01 Jun 2024 | UK£3.0b | UK£836.3m | -UK£287,266,028.40 | 30.6x | -10.3x | 3.6x |
| Mon, 29 Apr 2024 | UK£3.1b | UK£895.9m | -UK£215,717,681.40 | 29.7x | -14.4x | 3.5x |
| Wed, 27 Mar 2024 | UK£3.1b | UK£903.1m | -UK£202,183,517.28 | 28.5x | -15.4x | 3.5x |
| Fri, 23 Feb 2024 | UK£3.2b | UK£913.3m | -UK£197,835,821.65 | 31.2x | -16.2x | 3.5x |
| Sun, 21 Jan 2024 | UK£6.4b | UK£1.3b | -UK£245,297,001.00 | 37.3x | -25.9x | 5x |
| Tue, 19 Dec 2023 | UK£6.1b | UK£1.3b | -UK£245,590,728.00 | 37x | -25x | 4.8x |
| Thu, 16 Nov 2023 | UK£6.5b | UK£1.3b | -UK£242,394,041.00 | 39.3x | -26.6x | 5.1x |
| Sat, 14 Oct 2023 | UK£6.6b | UK£1.3b | -UK£251,319,262.00 | 38.4x | -26.1x | 5.1x |
| Mon, 11 Sep 2023 | UK£6.5b | UK£1.3b | -UK£207,007,212.00 | 23.6x | -31.6x | 5.1x |
| Wed, 09 Aug 2023 | UK£6.8b | UK£1.3b | -UK£209,217,365.00 | 23.4x | -32.5x | 5.4x |
| Fri, 07 Jul 2023 | UK£6.7b | UK£1.3b | -UK£209,039,838.00 | 23.9x | -32x | 5.3x |
| Sun, 04 Jun 2023 | UK£7.0b | UK£1.3b | -UK£204,603,564.00 | 22.6x | -34.3x | 5.6x |
| Tue, 02 May 2023 | UK£7.1b | UK£1.3b | -UK£205,973,036.00 | 23.6x | -34.3x | 5.6x |
| Thu, 30 Mar 2023 | UK£7.1b | UK£1.2b | -UK£155,047,316.00 | 24x | -45.7x | 5.7x |
| Sat, 25 Feb 2023 | UK£7.4b | UK£1.2b | -UK£156,973,587.00 | 26.1x | -47.4x | 6x |
| Mon, 23 Jan 2023 | UK£7.7b | UK£1.2b | -UK£139,964,852.00 | 27.7x | -54.7x | 6.6x |
| Wed, 21 Dec 2022 | UK£7.4b | UK£1.2b | -UK£138,103,865.00 | 26.7x | -53.3x | 6.3x |
| Fri, 18 Nov 2022 | UK£7.8b | UK£1.2b | -UK£140,671,510.00 | 25.1x | -55.1x | 6.7x |
| Sun, 16 Oct 2022 | UK£7.0b | UK£1.2b | -UK£150,681,291.00 | 26.2x | -46.7x | 6.1x |
| Tue, 13 Sep 2022 | UK£7.6b | UK£1.1b | -UK£144,420,164.00 | 35.4x | -52.4x | 6.6x |
| Thu, 11 Aug 2022 | UK£7.4b | UK£1.1b | -UK£199,848,602.00 | 37.2x | -36.8x | 6.6x |
| Sat, 09 Jul 2022 | UK£7.1b | UK£1.1b | -UK£175,037,886.00 | 36.3x | -40.4x | 6.3x |
| Mon, 06 Jun 2022 | UK£7.1b | UK£1.1b | -UK£156,906,832.00 | 37.9x | -45.5x | 6.4x |
| Wed, 04 May 2022 | UK£7.2b | UK£1.1b | -UK£139,598,748.00 | 35x | -51.9x | 6.5x |
| Fri, 01 Apr 2022 | UK£7.3b | UK£1.1b | -UK£87,768,925.00 | 41.4x | -83.6x | 6.7x |
| Sun, 27 Feb 2022 | UK£7.7b | UK£1.1b | -UK£130,231,992.00 | 32.8x | -59.4x | 7.1x |
| Tue, 25 Jan 2022 | UK£8.7b | UK£1.1b | -UK£123,582,165.00 | 39.6x | -70.3x | 8x |
| Thu, 23 Dec 2021 | UK£11.2b | UK£1.1b | -UK£121,036,520.00 | 55x | -92.3x | 10.3x |
| Sat, 20 Nov 2021 | UK£11.9b | UK£1.1b | -UK£150,428,894.00 | 66.5x | -79.4x | 11x |
| Mon, 18 Oct 2021 | UK£12.1b | UK£1.1b | -UK£148,206,944.00 | 70.5x | -81.7x | 11x |
| Wed, 15 Sep 2021 | UK£12.2b | UK£1.1b | -UK£143,503,184.62 | 53x | -85.2x | 11.6x |
Price to Earnings Ratio
-85.2x
Current Industry PE
- Investors are pessimistic on the British Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.5x is higher than the industry's current PS ratio of 3.3x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 7.6% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | -2.40% | |
| Healthcare | -3.20% | |
| Biotech | -3.22% | |
| Biotech | -3.22% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| FARN Faron Pharmaceuticals Oy | UK£2.24 | 9.3% +UK£19.9m | -30.0% | PB201.3x | |
| AVCT Avacta Group | UK£0.73 | 2.0% +UK£6.5m | -34.9% | PS11.3x | |
| ONC Oncimmune Holdings | UK£0.19 | 10.5% +UK£1.4m | 5.1% | PS11.8x | |
| TRX Tissue Regenix Group | UK£0.64 | 1.6% +UK£712.3k | 18.5% | PS2x | |
| SCLP Scancell Holdings | UK£0.17 | 0.3% +UK£464.8k | 76.9% | PE-16.8x |
